Q9Y233 | SWISS-MODEL Repository

Q9Y233 (PDE10_HUMAN) Homo sapiens (Human)

cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A UniProtKB InterPro STRING Interactive Modelling

It is possible new templates exist for this target since these models were created.

However, an attempt to improve models for this target was made on 2021-03-07. The outcome - only low quality models could be built.

		515	Proton donor
		519	Divalent metal cation 1
		553	Divalent metal cation 1
		554	Divalent metal cation 1
		554	Divalent metal cation 2
		664	Divalent metal cation 1
		97	Y -> C (in IOLOD; decreased protein abundance; dbSNP:rs778899140) VAR_076798 dbSNP
		106	A -> P (in IOLOD; decreased protein abundance; dbSNP:rs875989839) VAR_076799 dbSNP
		290	F -> L (in ADSD2; no effect on basal 3',5'-cyclic- nucleotide phosphodiesterase activity; the mutation severely disrupts the stimulatory effect on the enzyme activity mediated by cAMP binding; dbSNP:rs875989841) VAR_076800 dbSNP
		303	L -> P VAR_008797
		324	F -> L (in ADSD2; no effect on basal 3',5'-cyclic- nucleotide phosphodiesterase activity; the mutation severely disrupts the stimulatory effect on the enzyme activity mediated by cAMP binding; dbSNP:rs875989840) VAR_076801 dbSNP
		706	R -> K (in dbSNP:rs2224252) VAR_047822 dbSNP
		707	D -> N (in dbSNP:rs2860112) VAR_047823 dbSNP
		94-215	GAF domain IPR003018 PF01590
		267-412	GAF domain IPR003018 PF01590
		514-745	3'5'-cyclic nucleotide phosphodiesterase, catalytic domain IPR002073 PF00233

Experimental structures

Description	Oligo-state	Ligands	Structure	Range
Crystal Structure of PDE10A with a biaryl ether inhibitor (1-(1-(3-(4-(benzo[d]thiazol-2-ylamino)ph…	homo-3-mer	6×ZN; 24×SO4; 3×GOL; 3×15H;	4hf4	442-759
Assess
Crystal Structure of PDE10A with a biaryl ether inhibitor ((1-(3-(4-((1H-benzo[d]imidazol-2-yl)amin…	homo-3-mer	6×ZN; 18×SO4; 3×15J;	4heu	442-759
Assess
PDE10a Crystal Structure Complexed with Novel Inhibitor	homo-3-mer	6×ZN; 21×SO4; 3×0JQ;	4ddl	442-759
Assess
Crystal Structure of PDE10A with Imidazo[4,5-b]pyridines as Potent and Selective Inhibitors	homo-3-mer	6×ZN; 36×SO4; 15×GOL; 3×2KR;	4p1r	442-759
Assess
Crystal structure of PDE10a with a novel Imidazo[4,5-b]pyridine inhibitor	homo-3-mer	3×1IS; 3×1IR; 6×ZN; 6×SO4; 3×GOL;	4p0n	453-759
Assess
2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors	homo-3-mer	6×ZN; 21×SO4; 3×GOL; 3×35D;	4tpp	453-757
Assess
Crystal structure of 2-(3-alkoxy-1-azetidinyl) quinolines as PDE10A Inhibitors	homo-3-mer	21×SO4; 3×GOL; 3×35E; 6×ZN;	4tpm	454-756
Assess
Identification and structural characterization of PDE10 fragment inhibitors	homo-2-mer	2×ZN; 2×MG; 1×F03;	4ajf	439-764
Assess
2-[2-(4-Phenyl-1H-imidazol-2-yl)ethyl]quinoxaline (Sunovion Compound 14) co-crystallized with PDE10A	homo-2-mer	2×ZN; 2×MG; 2×4F7;	4yqh	439-759
Assess
PDE10 complexed with 4-isopropoxy-2-(2-(3-(4-methoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)…	homo-2-mer	2×ZN; 2×MG; 1×4PX; 1×4Q0;	4zo5	439-759
Assess
Co-crystal structure of 2-[2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethyl]-3-methyl-3H-imi…	homo-2-mer	2×ZN; 2×MG; 2×4GK;	4ys7	439-759
Assess
Crystal Structure of PDE10A with Novel Keto-Benzimidazole Inhibitor	homo-2-mer	4×ZN; 15×SO4; 1×GOL; 2×2F4;	4muw	442-759
Assess
Crystal structure of the catalytic domain of PDE10A complexed with 1-(2-fluoro-4-(1H-pyrazol-1-yl)p…	homo-2-mer	2×MG; 2×ZN; 2×3K9;	3wym	445-759
Assess
Crystal structure of the catalytic domain of PDE10A complexed with 3-(1-phenyl-1H-pyrazol-5-yl)-1-(…	homo-2-mer	2×MG; 2×ZN; 2×3KG;	3wyk	445-759
Assess
Crystal Structure of PDE10A with Novel Keto-Benzimidazole Inhibitor	homo-2-mer	4×ZN; 12×SO4; 2×2F5;	4mvh	452-759
Assess
Crystal Structure of PDE10A with 1H-benzimidazol-2-yl(4-((3-(tetrahydro-2H-pyran-4-yl)-2-pyridinyl)…	homo-2-mer	4×ZN; 6×SO4; 2×2W1;	4phw	454-758
Assess
Crystal structure of the C-terminal GAF domain of human phosphodiesterase 10A	homo-2-mer	2×CMP;	2zmf	246-422
Assess
Crystal structure of PDE10A2 with fragment ZT450	monomer	1×7ZE; 2×NI;	4lm1	439-767
Assess
Crystal structure of PDE10A2 with fragment ZT464	monomer	1×9ZE; 2×NI; 2×EDO;	4lm3	439-766
Assess
crystal structure of pde10a2 mutant D564A in complex with cAMP.	monomer	1×ZN; 1×MG; 1×CMP;	2ouy	439-766
Assess
Crystal structure of PDE10A2 with fragment ZT902	monomer	1×JPZ; 2×NI;	4lm4	439-765
Assess
Crystal structure of PDE10A2 with fragment ZT217	monomer	1×MEW; 2×NI;	4llk	439-765
Assess
Crystal structure of PDE10A2 with fragment ZT462	monomer	1×8ZE; 2×NI;	4lm2	439-765
Assess
Crystal structure of PDE10A2 with fragment ZT214	monomer	1×1XN; 2×NI;	4llj	439-765
Assess
Crystal structure of PDE10A2 with fragment ZT0429 (4-methyl-3-nitropyridin-2-amine)	monomer	1×2ZV; 2×NI;	4mrz	439-765
Assess
Crystal structure of PDE10A2 with fragment ZT0449 (5-nitro-1H-benzimidazole)	monomer	2×2ZM; 2×NI;	4msa	439-765
Assess
Crystal structure of PDE10A2 with fragment ZT017	monomer	1×1XM; 2×NI;	4lkq	439-765
Assess
Crystal structure of PDE10A2 with fragment ZT448	monomer	1×5NI; 2×NI;	4lm0	439-765
Assess
Crystal structure of PDE10A2 with fragment ZT434	monomer	1×5ZE; 2×NI;	4llx	439-765
Assess
Crystal structure of PDE10A2 with fragment ZT401	monomer	2×4ZE; 2×NI;	4llp	439-765
Assess
Crystal structure of PDE10A2 with fragment ZT0443 (6-chloropyrimidine-2,4-diamine)	monomer	1×2ZX; 2×NI;	4ms0	439-765
Assess
Crystal structure of PDE10A2 with fragment ZT0120 (7-chloroquinolin-4-ol)	monomer	1×MRW; 2×NI;	4mrw	439-765
Assess
Crystal structure of PDE10A2 with fragment ZT0451 (8-nitroquinoline)	monomer	1×2ZQ; 2×NI;	4msn	439-765
Assess
Crystal structure of PDE10A2 with fragment ZT1595 (2-[(quinolin-7-yloxy)methyl]quinoline)	monomer	1×2ZT; 2×NI;	4msc	439-765
Assess
Crystal structure of PDE10A2 with fragment ZT1597 (2-({[(2S)-2-methyl-2,3-dihydro-1,3-benzothiazol-…	monomer	1×2ZU; 2×NI;	4mse	439-765
Assess
crystal structure of PDE10A2 mutant D674A in complex with cGMP	monomer	1×MG; 3×35G;	2ouu	439-764
Assess
Novel, potent, selective and brain penetrant phosphodiesterase 10A inhibitors	monomer	1×ZN; 1×MG; 1×JY4;	6msa	439-764
Assess
Crystal Structure of PDE10A2 with fragment ZT0143 ((2S)-4-chloro-2,3-dihydro-1,3-benzothiazol-2-ami…	monomer	1×2D0; 2×NI;	4msh	439-764
Assess
crystal structure of PDE10A2 in complex with GMP	monomer	1×ZN; 1×MG; 1×5GP;	2ouq	439-762
Assess
Human PDE-papaverine complex obtained by ligand soaking of cross- linked protein crystals	monomer	1×EV1; 1×ZN; 1×MG;	2wey	437-760
Assess
crystal structure of PDE10A2 mutant D674A	monomer	1×MG;	2ous	439-761
Assess
PDE10 complexed with 6-chloro-2-cyclopropyl-5-methyl-pyrimidin-4-amine	monomer	1×ZN; 1×MG; 1×4XV;	5c28	439-761
Assess
crystal structure of pde10a2 mutant of D564N	monomer	1×ZN; 1×MG;	2ouv	439-761
Assess
PDE10 complexed with 4,6-dichloro-2-cyclopropyl-5-methyl-pyrimidine	monomer	1×ZN; 1×MG; 1×4XS;	5c1w	439-761
Assess
PDE10 complexed with N-[(1-methylpyrazol-4-yl)methyl]-5-[[(1S,2S)-2-(2-pyridyl)cyclopropyl]methoxy]…	monomer	1×ZN; 1×MG; 1×5AY;	5dh5	448-770
Assess
crystal structure of PDE10A2 mutant D674A in complex with cAMP	monomer	1×MG; 1×CMP;	2our	439-760
Assess
crystal structure of PDE10A	monomer	1×ZN; 1×MG;	2oup	439-760
Assess
crystal structure of PDE10A2 in complex with AMP	monomer	1×ZN; 1×MG; 1×AMP;	2oun	439-760
Assess
Crystal structure of PDE10A in complex with ASP9436	monomer	1×ZN; 1×MG; 1×490;	4xy2	439-760
Assess
Crystal structure of PDE10A in complex with inhibitor	monomer	1×ZN; 1×MG; 1×P98;	3wi2	439-760
Assess
Identification and structural characterization of PDE10 fragment inhibitors	monomer	1×ZN; 1×MG; 1×F04;	4ajd	439-760
Assess
Crystal structure of PDE10A in complex with a triazolopyrimidine inhibitor	monomer	1×ZN; 1×MG; 1×D6X;	6kdx	439-760
Assess
Crystal structure of PDE10A in complex with a benzimidazole inhibitor	monomer	1×ZN; 1×MG; 1×X4C;	3ws8	439-760
Assess
Crystal structure of PDE10 in complex with inhibitor 2b	monomer	1×ZN; 1×MG;	6iji	439-760
Assess
Crystal structure of PDE10A catalytic domain complexed with LHB-6	monomer	1×ZN; 1×MG; 1×9G6;	5znl	439-760
Assess
Crystal structure of PDE10A in complex with a triazolopyrimidine inhibitor	monomer	1×ZN; 1×MG; 1×D7C;	6ke0	439-760
Assess
Crystal structure of PDE10A in complex with a benzimdazole inhibitor	monomer	1×ZN; 1×MG; 1×X4D;	3ws9	439-760
Assess
Crystal structure of PDE10A in complex with a triazolopyrimidine inhibitor	monomer	1×ZN; 1×MG; 1×D79;	6kdz	439-760
Assess
Crystal structure of PDE10A in complex with 1-methyl-5-(1-methyl-3-{[4-(quinolin-2-yl)phenoxy]methy…	monomer	1×ZN; 1×MG; 1×3SJ;	4wn1	439-760
Assess
Highly Potent, Selective, and Orally Active Phosphodiestarase 10A Inhibitors	monomer	1×CL; 1×540; 1×ZN; 1×MG;	3sn7	439-759
Assess
Highly Potent, Selective, and Orally Active Phosphodiestarase 10A Inhibitors	monomer	1×ZN; 1×MG; 1×CL; 1×546;	3sni	439-759
Assess
PDE10 complexed with 6-chloro-2-cyclopropyl-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-pyrimidin…	monomer	1×ZN; 1×MG; 1×4Y2;	5c2a	439-759
Assess
Potent and Selective Phosphodiesterase 10A Inhibitors	monomer	1×ZN; 1×MG; 1×0T6;	4fcd	439-759
Assess
PDE10 complexed with6-chloro-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[2-(2-pyridyl)ethoxy]p…	monomer	1×ZN; 1×MG; 1×4PX;	5c2e	439-759
Assess
Potent and Selective Phosphodiesterase 10A Inhibitors	monomer	1×ZN; 1×MG; 1×0T7;	4fcb	439-759
Assess
Novel, potent, selective and brain penetrant phosphodiesterase 10A inhibitors	monomer	1×ZN; 1×MG; 1×JY7;	6msc	439-759
Assess
Highly Potent, Selective, and Orally Active Phosphodiestarase 10A Inhibitors	monomer	1×ZN; 1×MG;	3snl	439-759
Assess
Crystal structure of PDE10A in complex with 7-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]pyrimidine	monomer	1×ZN; 1×MG; 1×8G6;	5xuj	439-759
Assess
Crystal structure of PDE10A in complex with 2-methyl-5-[2-([1,2,4]triazolo[1,5-a]pyrimidin-2-yl)et …	monomer	1×ZN; 1×MG; 1×8G3;	5xui	439-759
Assess
Crystal structure of human PDE10A in complex with inhibitor 16d	monomer	1×8Q7; 1×ZN; 1×MG;	5uwf	439-758
Assess
PDE10 complexed with 6-chloro-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[3-(2-quinolyl)propox…	monomer	1×ZN; 1×MG; 1×4XU;	5c2h	439-758
Assess
Identification and structural characterization of PDE10 fragment inhibitors	monomer	1×ZN; 1×MG; 1×F07;	4ajg	439-758
Assess
Crystal structure of PDE10 in complex with inhibitor AF-399/14387019	monomer	1×ZN; 1×MG; 1×AEO;	6ijh	439-758
Assess
PDE10A in complex with the inhibitor AZ5	monomer	1×ZN; 1×MG; 1×4HN;	4ael	439-757
Assess
Development of a plate-based optical biosensor methodology to identify PDE10 fragment inhibitors	monomer	1×ZN; 1×MG;	4ajm	439-756
Assess
Crystal structure of the catalytic domain of PDE10A complexed with highly potent and brain-penetran…	monomer	1×MG; 1×ZN; 1×4LP;	5axq	445-759
Assess
Crystal structure of the catalytic domain of PDE10A complexed with 1-(2-fluoro-4-(2-oxo-1,3-oxazoli…	monomer	1×MG; 1×ZN; 1×4LK;	5axp	445-759
Assess
Discovery of orally active pyrazoloquinoline as a potent PDE10 inhibitor for the management of schi…	monomer	1×C1L; 1×MG; 1×ZN;	3ui7	446-760
Assess
Crystal structure of the catalytic domain of human PDE10A complexed with 1-(cyclopropylmethyl)-5-(2…	monomer	1×MG; 1×ZN; 1×6DW;	5b4l	445-759
Assess
Crystal structure of the catalytic domain of PDE10A complexed with 5-methoxy-3-(1-phenyl-1H-pyrazol…	monomer	1×ZN; 1×MG; 1×3KB;	3wyl	445-759
Assess
Crystal structure of the catalytic domain of human PDE10A complexed with N-(4-((5-methyl-5H-pyrrolo…	monomer	1×MG; 1×ZN; 1×6DT;	5b4k	445-759
Assess
human PDE10A in complex with 1-(4-Chloro-phenyl)-3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxylic aci…	monomer	1×ZN; 1×MG; 1×GOL; 1×5M6;	5ede	447-760
Assess
Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors, part 2, Lead-op…	monomer	1×AXC; 1×ZN; 1×MG;	2y0j	446-759
Assess
human PDE10A, 6-Chloro-5,8-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-2H-[1,2,4]triazol-3-yl)-ethyl]…	monomer	1×ZN; 1×MG; 1×5M9;	5edi	448-760
Assess
human PDE10A in complex with 3-(2-Chloro-5-phenyl-3H-imidazol-4-yl)-1-(3-trifluoromethoxy-phenyl)-1…	monomer	1×ZN; 1×MG; 1×5MG;	5edg	448-760
Assess
human PDE10A in complex with 3-(2-phenylpyrazol-3-yl)-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one	monomer	1×ZN; 1×MG; 1×67A;	5i2r	448-760
Assess
human PDE10A, 8-ethyl-5-methyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]tr…	monomer	1×ZN; 1×MG; 1×5MF;	5edh	449-760
Assess
The crystal structue of PDE10A complexed with 14	monomer	1×ZN; 1×MG; 1×DZU;	7bpi	448-759
Assess
Discovery of a potent, selective and orally active PDE10A inhibitor for the treatment of schizophre…	monomer	1×LKF; 1×ZN; 1×MG;	4bbx	448-759
Assess
PDE10a with imidazopyrazine inhibitor	monomer	1×ZN; 1×MG; 1×6RC;	5k9r	448-759
Assess
The crystal structue of PDE10A complexed with 2d	monomer	1×ZN; 1×MG; 1×DL0;	6ko1	450-759
Assess
The crystal structue of PDE10A complexed with 1i	monomer	1×DKU; 1×ZN; 1×MG;	6ko0	452-759
Assess
PDE10 complexed with 6-chloro-2-cyclopropyl-5-methyl-N-propyl-pyrimidin-4-amine	monomer	1×ZN; 1×MG; 1×4XY;	5c29	454-760
Assess
The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors f…	monomer	1×MG; 1×ZN;	4dff	453-759
Assess
PDE10 complexed with 5-chloro-N-[(2,4-dimethylthiazol-5-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine	monomer	1×ZN; 1×MG; 1×5AV; 1×4PX;	5dh4	451-757
Assess
The crystal structue of PDE10A complexed with 4d	monomer	1×DZU; 1×ZN; 1×MG;	6kze	453-758
Assess
The discovery of potent, selectivity, and orally bioavailable pyrozoloquinolines as PDE10 inhibitor…	monomer	1×0CV; 1×MG; 1×ZN; 1×PO4;	3uuo	455-759
Assess

Homology models

Oligo-state	QMEAN	Template	Range	Seq id (%)	Ligands
monomer	-4.31	1mc0.1.A	73-426	27.83
Assess

Homology models built on isoform sequence

Isoform	Oligo-state	QMEAN	Template	Range	Seq id (%)
Isoform 2	monomer	-3.70	1mc0.1.A	99-436	28.53
Assess
Isoform 2	monomer	-4.95	6mzb.1.B	30-770	25.75
Assess

Q9Y233 (PDE10_HUMAN) Homo sapiens (Human)

cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A UniProtKBInterProSTRINGInteractive Modelling

Homology Model

Model Quality Estimate

Sequence Features

Sequence Alignments

Experimental structures

Homology models

Homology models built on isoform sequence

Background

Resolution

cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A UniProtKB InterPro STRING Interactive Modelling